Quantic Analysis of Formation of a Biomaterial of Latex, Retinol, and Chitosan for Biomedical Applications

The present work shows the quantum theoretical analysis and practical tests for the formation of a homogeneous mixture with Latex (Lx), Chitosan (Qn) and Retinol (Rl), which work as possible biomaterial for regeneration of epithelial tissue. Lx, Qn, and Rl compounds molecules were designed through Hyperchem to get the coefficient of electrostatic potential calculations. The amounts used to create the biomaterial are minimum depending on the quantities of molecules used in chemical design. A positive calculation was obtained for the reaction of these three compounds and the formation of the biomaterial in physical checking theory etc

Quantic Analysis of the Adherence of a Gram-Negative Bacteria in A HEPA Filter

It is known that Gram-negative bacteria (GNB) are the most frequent bacteria in hospital units. It is also known that GNBs generate a greater number of nosocomial infections in critical areas. In the present work, the adhesion of the bacterial cell wall (BCW) to the compounds of the material layers of a high efficiency filter (HEPA) was analyzed. The analysis was carried out by means of molecular simulation and quantum chemistry. The BCW and HEPA molecules were designed using Hyperchem software for simulation. The calculations of the quantum interactions of the molecules were carried out using the theory of the electron transfer coefficient (ETC). It obtained from 4 to 6 compounds that are more likely to interact even as a chemical reaction. The compounds of the glass fibers are the ones that work best for the adhesion and destruction of the BCW

América Latina : sociedad, política y salud en tiempos de pandemia

Actualmente es indiscutible que la pandemia de COVID-19 es el acontecimiento contemporáneo de salud más importante. Ha irrumpido con fuerza en la cotidianidad de los países, ciudades, comunidades y familias. Sin embargo, parece necesario tener presente que es un advenimiento en progreso y no tenemos certeza sobre el curso que tomará y cuales serán sus ulteriores efectos. Esto significa que cualquier reflexión sobre COVID-19 es preliminar. Con el transcurrir de los últimos seis meses la pandemia se ha convertido en tema obligado en las primeras planas de los periódicos. Ha desatado un debate en el cual muchos se sienten con la competencia para opinar, apoyar o rechazar la actuación de los gobiernos. Ante los cuestionamientos los gobiernos han creado su propia narrativa sobre lo que están haciendo. La pandemia es en este sentido un tema altamente politizada. La epidemia de SARS-CoV-2 confluye con otro proceso de largo alcance que es la transformación de inspiración neoliberal de los sistemas de salud desde por lo menos tres o cuatro décadas. Otro proceso en los orígenes de la epidemia es el acelerado deterioro del medio ambiente y el calentamiento global que está trastocando los ecosistemas en todo el planeta. En su determinación está entonces la confluencia de tres grandes procesos que caracterizan a la globalización. Éstos a su vez se irradian en toda la sociedad y tienen efectos sobre otros procesos. Del prólogo de Asa Cristina Laurel

Memorias del primer Simposio Nacional de Ciencias Agronómicas

Primer simposio nacional de Ciencias Agronómicas: El renacer del espacio de discusión científica para el Agro colombiano

Memorias del primer Simposio Nacional de Ciencias Agronómicas

Primer simposio nacional de Ciencias Agronómicas: El renacer del espacio de discusión científica para el Agro colombiano

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score–matched models. Results: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9–3.6], 4.0 [95% CI, 3.6–4.5], and 5.5 [95% CI, 5.0–6.1] events per 100 patient-years in strata 35–<50, and ≤35 mg/dL, respectively). Compared with propensity score–matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol but not vice versa. Conclusions: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.gov; Unique identifier: NCT01663402.URL: https://www